Stroke RSS

Filtered By:
Specialty: Drugs & Pharmacology
Condition: Osteoporosis
Drug: Forteo

Filter By:
Specialty
Source
Condition
Cancer
Infectious Disease
Drug
Training
Management
Procedure
Therapy
Vaccine
Nutrition
Country

This page shows you your search results in order of date.

Order by Relevance | Date

Total 1 results found since Jan 2013.

Romosozumab: A Novel Injectable Sclerostin Inhibitor With Anabolic and Antiresorptive Effects for Osteoporosis.
CONCLUSIONS: Romosozumab offers an alternative for patients with a high risk of osteoporotic fractures. Clinicians should avoid romosozumab in patients with a history of myocardial infarction or stroke in the past 12 months. PMID: 32862655 [PubMed - as supplied by publisher]
Source: The Annals of Pharmacotherapy - August 28, 2020 Category: Drugs & Pharmacology Authors: Nealy KL, Harris KB Tags: Ann Pharmacother Source Type: research